Overcoming Poor Aqueous Solubility of Drugs for Oral Delivery
暂无分享,去创建一个
[1] G. Murphy,et al. Estracyt (NSC 89199) as a substrate for phosphatases in human serum. , 1974, Investigative urology.
[2] Y. Kiso,et al. Effect of the acyl groups on O-->N acyl migration in the water-soluble prodrugs of HIV-1 protease inhibitor. , 2003, Bioorganic & medicinal chemistry letters.
[3] J. Therrien,et al. A prodrug approach toward the development of water soluble fluoroquinolones and structure--activity relationships of quinoline-3-carboxylic acids. , 2004, Journal of medicinal chemistry.
[4] G. Amidon,et al. Improving intestinal absorption of water-insoluble compounds: a membrane metabolism strategy. , 1980, Journal of pharmaceutical sciences.
[5] J. Dressman,et al. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. , 1997, Advanced drug delivery reviews.
[6] S. Ekins,et al. Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. , 2002, Molecular pharmacology.
[7] D. E. Duggan,et al. Sulindac: therapeutic implications of the prodrug/pharmacophore equilibrium. , 1981, Drug metabolism reviews.
[8] S. Chong,et al. Prodrugs of BMS-183920: metabolism and permeability considerations. , 1996, Journal of pharmaceutical sciences.
[9] D. Fleisher,et al. Regional-dependent intestinal absorption and meal composition effects on systemic availability of LY303366, a lipopeptide antifungal agent, in dogs. , 2001, Journal of pharmaceutical sciences.
[10] R. Pettit,et al. Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate. , 2002, Journal of medicinal chemistry.
[11] R. Notari. Prodrug design. , 1981, Pharmacology & therapeutics.
[12] Joseph W. Polli,et al. Role of P-Glycoprotein on the CNS Disposition of Amprenavir (141W94), an HIV Protease Inhibitor , 1999, Pharmaceutical Research.
[13] W. L. Chiou,et al. Evaluation of potential causes for the incomplete bioavailability of furosemide: Gastric first-pass metabolism , 1983, Journal of Pharmacokinetics and Biopharmaceutics.
[14] Richard B Greenwald,et al. Effective drug delivery by PEGylated drug conjugates. , 2003, Advanced drug delivery reviews.
[15] J. Leppänen,et al. Synthesis of a water-soluble prodrug of entacapone. , 2000, Bioorganic & medicinal chemistry letters.
[16] B. Jo,et al. Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. , 2004, International journal of pharmaceutics.
[17] D. Bolikal,et al. HIGHLY WATER SOLUBLE TAXOL DERIVATIVES : 7-POLYETHYLENE GLYCOL CARBAMATES AND CARBONATES , 1995 .
[18] Bernard Testa,et al. Lessons Learned from Marketed and Investigational Prodrugs. , 2004 .
[19] V. Stella,et al. Hydrolysis of pharmaceutically relevant phosphate monoester monoanions: correlation to an established structure-reactivity relationship. , 1993, Journal of pharmaceutical sciences.
[20] R. Moss,et al. Propofol Phosphate, a Water-Soluble Propofol Prodrug:In Vivo Evaluation , 2002, Anesthesia and analgesia.
[21] Y. Kiso,et al. Controlled drug release: new water-soluble prodrugs of an HIV protease inhibitor. , 2001, Bioorganic & medicinal chemistry letters.
[22] N R Hunter,et al. Synthesis and evaluation of water-soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug , 1996, Anti-cancer drugs.
[23] F. Schabel,et al. Biologic activity of 9-β-d-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-d-arabinofuranosyladenine , 1977 .
[24] G. Flynn,et al. Absorption Rate Limit Considerations for Oral Phosphate Prodrugs , 2003, Pharmaceutical Research.
[25] D. Winne. Shift of pH-absorption curves , 1977, Journal of Pharmacokinetics and Biopharmaceutics.
[26] W. Prince,et al. Pharmacokinetics of GW433908, a Prodrug of Amprenavir, in Healthy Male Volunteers , 2002, Journal of clinical pharmacology.
[27] H. Stellbrink,et al. Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients , 2004, Antimicrobial Agents and Chemotherapy.
[28] D. Kerr,et al. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] D. Chaplin,et al. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503. , 2002, Anticancer research.
[30] V. Stella,et al. A novel prodrug approach for tertiary amines. 3. In vivo evaluation of two N-phosphonooxymethyl prodrugs in rats and dogs. , 1999, Journal of pharmaceutical sciences.
[31] R. Strickley. Solubilizing Excipients in Oral and Injectable Formulations , 2004, Pharmaceutical Research.
[32] H. Maeda,et al. Tumoritropic and lymphotropic principles of macromolecular drugs. , 1989, Critical reviews in therapeutic drug carrier systems.
[33] Y. Kiso,et al. Water-soluble prodrugs of dipeptide HIV protease inhibitors based on O-->N intramolecular acyl migration: Design, synthesis and kinetic study. , 2004, Bioorganic & medicinal chemistry.
[34] C. Waters,et al. Entacapone in the management of Parkinson’s disease , 2002, Expert opinion on pharmacotherapy.
[35] G. Layton,et al. Pharmacokinetics of fosfluconazole and fluconazole following multiple intravenous administration of fosfluconazole in healthy male volunteers. , 2004, British journal of clinical pharmacology.
[36] D. Chaplin,et al. Combretastatin A4 phosphate: background and current clinical status , 2004, Expert opinion on investigational drugs.
[37] R. Liu. Water-insoluble drug formulation , 2000 .
[38] A. Burstein,et al. Phenytoin pharmacokinetics following oral administration of phenytoin suspension and fosphenytoin solution to rats , 1999, Epilepsy Research.
[39] Youn-Chul Kim,et al. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[40] G. Amidon,et al. Improving the intestinal mucosal cell uptake of water insoluble compounds , 1985 .
[41] R. N. Brogden,et al. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer. , 1995, Drugs & aging.
[42] N. Rodríguez-Hornedo,et al. Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs. , 2003, International journal of pharmaceutics.
[43] E. Suzuki,et al. Dose-dependent gastrointestinal absorption of 5-fluorouracil in rats in vivo. , 1996, Biological & pharmaceutical bulletin.
[44] R. Barrett,et al. XP13512 [(±)-1-([(α-Isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane Acetic Acid], A Novel Gabapentin Prodrug: II. Improved Oral Bioavailability, Dose Proportionality, and Colonic Absorption Compared with Gabapentin in Rats and Monkeys , 2004, Journal of Pharmacology and Experimental Therapeutics.
[45] P. Neuvonen. Bioavailability of Phenytoin: Clinical Pharmacokinetic and Therapeutic Implications , 1979, Clinical pharmacokinetics.
[46] K. Goa,et al. Amprenavir: a review of its clinical potential in patients with HIV infection. , 2000, Drugs.
[47] S. Varia,et al. Phenytoin prodrugs V: In vivo evaluation of some water-soluble phenytoin prodrugs in dogs. , 1984, Journal of pharmaceutical sciences.
[48] E. De Clercq,et al. Increased absorption of the antiviral ester prodrug tenofovir disoproxil in rat ileum by inhibiting its intestinal metabolism. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[49] J. Rothbard,et al. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation , 2000, Nature Medicine.
[50] Edward B. Roche,et al. Design of biopharmaceutical properties through prodrugs and analogs , 1977 .
[51] T. Shen,et al. Chemical and biological studies on indomethacin, sulindac and their analogs. , 1977, Advances in drug research.
[52] L. Schacter. Etoposide phosphate: what, why, where, and how? , 1996, Seminars in oncology.
[53] M. Grever,et al. A comprehensive phase I and II clinical investigation of fludarabine phosphate. , 1990, Seminars in oncology.
[54] P. Heinrich Stahl,et al. 35 – PREPARATION OF WATER-SOLUBLE COMPOUNDS THROUGH SALT FORMATION , 2003 .
[55] S. Croft,et al. Synthesis and antileishmanial activity of novel buparvaquone oxime derivatives. , 2004, Bioorganic & medicinal chemistry.
[56] A. Noyes,et al. The rate of solution of solid substances in their own solutions , 1897 .
[57] B. Ruggeri,et al. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clini , 2003, Journal of medicinal chemistry.
[58] A. Kashuba,et al. Fosamprenavir. Vertex Pharmaceuticals/GlaxoSmithKline. , 2002, Current opinion in investigational drugs.
[59] M. Bowker,et al. Preparation of Water-Soluble Compounds Through Salt Formation , 2008 .
[60] A. Selen. Factors influencing bioavailability and bioequivalence , 1991 .
[61] Yingjin Yuan,et al. Synthesis and evaluation of water-soluble paclitaxel prodrugs. , 2002, Bioorganic & medicinal chemistry letters.
[62] M. Mutter,et al. Cyclosporin A prodrugs: design, synthesis and biophysical properties. , 2008, The journal of peptide research : official journal of the American Peptide Society.
[63] P. Pentikäinen,et al. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man , 2001, European Journal of Clinical Pharmacology.
[64] Thomas J. Raub,et al. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. , 1989, Gastroenterology.
[65] J. Vepsäläinen,et al. Bisphosphonate prodrugs: synthesis and in vitro evaluation of alkyl and acyloxymethyl esters of etidronic acid as bioreversible prodrugs of etidronate. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[66] P. Wipf,et al. Synthesis of chemoreversible prodrugs of ara-C with variable time-release profiles. Biological evaluation of their apoptotic activity. , 1996, Bioorganic & medicinal chemistry.
[67] Anette Müllertz,et al. Dissolution of Hydrocortisone in Human and Simulated Intestinal Fluids , 2000, Pharmaceutical Research.
[68] Jiunn H. Lin,et al. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. , 2003, Advanced drug delivery reviews.
[69] V. Stella,et al. Some relationships between the physical properties of various 3-acyloxymethyl prodrugs of phenytoin to structure: potential in vivo performance implications. , 1998, Journal of pharmaceutical sciences.
[70] A. Nomeir,et al. Simultaneous high-performance liquid chromatographic determination of SCH 59884 (phosphate ester prodrug of SCH 56592), SCH 207962 and SCH 56592 in dog plasma. , 2002, Journal of pharmaceutical and biomedical analysis.
[71] T. Nilsson,et al. Clinical results with estramustine phosphate (NSC-89199): a comparison of the intravenous and oral preparations. , 1975, Cancer chemotherapy reports.
[72] Y. Kiso,et al. New water-soluble prodrugs of HIV protease inhibitors based on O-->N intramolecular acyl migration. , 2002, Bioorganic & medicinal chemistry.
[73] S. A. Hussain,et al. Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[74] Younggil Kwon,et al. Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists , 2001, Springer US.
[75] H. Zhao,et al. Drug delivery systems employing 1,4- or 1,6-elimination: poly(ethylene glycol) prodrugs of amine-containing compounds. , 1999, Journal of medicinal chemistry.
[76] B. Brodie,et al. The gastric secretion of drugs: a pH partition hypothesis. , 1957, The Journal of pharmacology and experimental therapeutics.
[77] H. Yuasa,et al. Effects of grinding and tableting on physicochemical stability of an anticancer drug, TAT-59. , 1996, Chemical & pharmaceutical bulletin.
[78] F. Ververs,et al. Absolute bioavailability of fluoride from disodium monofluorophosphate and enteric-coated sodium fluoride tablets , 1996, European Journal of Clinical Pharmacology.
[79] C. Porter,et al. A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. , 1996, Journal of pharmaceutical sciences.
[80] M. Skwarczynski,et al. A novel approach of water-soluble paclitaxel prodrug with no auxiliary and no byproduct: design and synthesis of isotaxel. , 2003, Journal of medicinal chemistry.
[81] W. Tong,et al. Preformulation Aspects of Insoluble Compounds , 2018 .
[82] S. Johansson,et al. Impairment of estramustine phosphate absorption by concurrent intake of milk and food , 2004, European Journal of Clinical Pharmacology.
[83] W. Bennett,et al. Effects of dimethyl sulfoxide on renal function in man. , 1980, JAMA.
[84] M. Engle,et al. Regulation of surfactant-like particle secretion by Caco-2 cells. , 2001, Biochimica et biophysica acta.
[85] M. Cho,et al. Metronidazole phosphate--a water-soluble prodrug for parenteral solutions of metronidazole. , 1982, Journal of pharmaceutical sciences.
[86] Antony D'Emanuele,et al. The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[87] R. Oliyai,et al. Structural Factors affecting the kinetics of O,N-acyl transfer in potential O-peptide prodrugs , 1995 .
[88] T. Fujiwara,et al. Development of Anti-Influenza Virus Drugs I: Improvement of Oral Absorption and In Vivo Anti-Influenza Activity of Stachyflin and Its Derivatives , 1999, Pharmaceutical Research.
[89] V. Stella. A case for prodrugs: Fosphenytoin , 1996 .
[90] T. Lister,et al. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] D. Oscier,et al. The bioavailability of oral fludarabine phosphate is unaffected by food. , 2001, The hematology journal : the official journal of the European Haematology Association.
[92] M. Grever,et al. High-dose combination chemotherapy with thiotepa and autologous hematopoietic stem cell reinfusion in the treatment of patients with relapsed refractory lymphomas. , 1990, Seminars in oncology.
[93] P. Anderson. Pharmacologic Perspectives for Once-Daily Antiretroviral Therapy , 2004, The Annals of pharmacotherapy.
[94] A. Nácher,et al. Nonlinear intestinal absorption kinetics of cefuroxime axetil in rats , 1997, Antimicrobial agents and chemotherapy.
[95] E. D. Barnhart. Physicians Desk Reference , 1990 .
[96] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[97] W. Rose,et al. Novel water soluble phosphate prodrugs of taxol® possessing in vivo antitumor activity , 1993 .
[98] S. Posen,et al. Clinical Utilization of Alkaline Phosphatase Measurements , 1979 .
[99] P. Sinko,et al. Carrier‐mediated intestinal absorption of valacyclovir, the L‐valyl ester prodrug of acyclovir. 1. Interactions with peptides, organic anions and organic cations in rats , 1998, Biopharmaceutics & drug disposition.
[100] A. Klein-Szanto,et al. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. , 2003, Cancer research.
[101] E. Schacht,et al. Review: Poly(Ethylene Glycol)s with Reactive Endgroups. II. Practical Consideration for the Preparation of Protein-PEG Conjugates , 1996 .
[102] G. Jolles,et al. Drug design : fact or fantasy? , 1984 .
[103] A. Bergenheim,et al. Pharmacokinetics and Pharmacodynamics of Estramustine Phosphate , 1998, Clinical pharmacokinetics.
[104] D. Fleisher,et al. Improved oral drug delivery: solubility limitations overcome by the use of prodrugs , 1996 .
[105] M. Bibby,et al. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug , 1999, British Journal of Cancer.
[106] T. Nevalainen,et al. Synthesis and in vitro/in vivo evaluation of novel oral N-alkyl- and N,N-dialkyl-carbamate esters of entacapone. , 2000, Life sciences.
[107] T. Heimbach. Oral phosphate prodrugs: Absorption rate limit considerations. , 2003 .
[108] R. Gugler,et al. Disposition of quercetin in man after single oral and intravenous doses , 1975, European Journal of Clinical Pharmacology.
[109] A. Mitra,et al. Pharmacokinetics of Novel Dipeptide Ester Prodrugs of Acyclovir after Oral Administration: Intestinal Absorption and Liver Metabolism , 2004, Journal of Pharmacology and Experimental Therapeutics.
[110] V. Stella,et al. When can cyclodextrins be considered for solubilization purposes? , 2003, Journal of pharmaceutical sciences.
[111] W. Turner,et al. The synthesis of water soluble prodrugs analogs of echinocandin B. , 1999, Bioorganic & medicinal chemistry letters.
[112] J. Rossi,et al. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[113] J. Guillet,et al. Drug Delivery Systems , 1995 .
[114] F. Bosch,et al. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[115] Sietsema Wk,et al. The absolute oral bioavailability of selected drugs , 1989 .
[116] J. Schellens,et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[117] G. Dubowchik,et al. Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. , 1998, Bioorganic & medicinal chemistry letters.
[118] A. Rigalli,et al. Gastric and intestinal absorption of monofluorophosphate and fluoride in the rat. , 1994, Arzneimittel-Forschung.
[119] S. Tamaki,et al. KY-109, a new bifunctional pro-drug of a cephalosporin. Chemistry, physico-chemical and biological properties. , 1985, Journal of antibiotics (Tokyo. 1968).
[120] P. Wipf,et al. Synthesis of chemoreversible prodrugs of ARA-C , 1991 .
[121] R. Borchardt,et al. Kinetics of diketopiperazine formation using model peptides. , 1998, Journal of pharmaceutical sciences.
[122] P. Vierling,et al. Transepithelial Transport of Prodrugs of the HIV Protease Inhibitors Saquinavir, Indinavir, and Nelfinavir Across Caco-2 Cell Monolayers , 2002, Pharmaceutical Research.
[123] S. Croft,et al. Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone. , 2004, Journal of medicinal chemistry.
[124] K. Ward,et al. Development of an in vivo preclinical screen model to estimate absorption and bioavailability of xenobiotics. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[125] O. H. Chan,et al. Evaluation of a Targeted Prodrug Strategy to Enhance Oral Absorption of Poorly Water-Soluble Compounds , 1998, Pharmaceutical Research.
[126] Jivn R. Chen,et al. Preformulation Study of Etoposide: Identification of Physicochemical Characteristics Responsible for the Low and Erratic Oral Bioavailability of Etoposide , 1989, Pharmaceutical Research.
[127] A. Otaka,et al. Convenient one-pot synthesis of cystine-containing peptides using the trimethylsilyl chloride–dimethyl sulfoxide/trifluoroacetic acid system and its application to the synthesis of bifunctional anti-HIV compounds1 , 1998 .
[128] R. Müller,et al. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. , 2001, Advanced drug delivery reviews.
[129] M. Bodanszky,et al. Side reactions in peptide synthesis. VII. Sequence dependence in the formation of aminosuccinyl derivatives from beta-benzyl-aspartyl peptides. , 2009, International journal of peptide and protein research.
[130] K. Beaumont,et al. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. , 2003, Current drug metabolism.
[131] M. Butters,et al. The Discovery and Process Development of a Commercial Route to the Water Soluble Prodrug, Fosfluconazole , 2002 .
[132] Lawrence X. Yu. An Integrated Model for Determining Causes of Poor Oral Drug Absorption , 1999, Pharmaceutical Research.
[133] M. Skwarczynski,et al. O-N intramolecular acyl migration strategy in water-soluble prodrugs of taxoids. , 2003, Bioorganic & medicinal chemistry letters.
[134] Carlota Saldanha,et al. Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects. , 2003, Biochemical pharmacology.
[135] Hoon Cho,et al. Water soluble cyclosporine monomethoxy poly(ethyleneglycol) conjugates as potential prodrugs , 2004, Archives of pharmacal research.
[136] K. Kobe. The properties of gases and liquids , 1959 .
[137] N. Davies,et al. Clinical Pharmacokinetics of Sulindac , 1997, Clinical pharmacokinetics.
[138] K. Järvinen,et al. Effects of aqueous solubility and dissolution characteristics on oral bioavailability of entacapone , 2000 .
[139] Ronald T. Borchardt,et al. Pharmaceutical profiling in drug discovery for lead selection , 2004 .
[140] E. Furfine,et al. Preclinical Pharmacology and Pharmacokinetics of GW433908, a Water-Soluble Prodrug of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir , 2004, Antimicrobial Agents and Chemotherapy.
[141] G. Flynn,et al. Factors influencing solvolysis of corticosteroid-21-phosphate esters. , 1970, Journal of pharmaceutical sciences.
[142] C. Lipinski. Poor aqueous solubility-an industry wide problem in drug discovery , 2002 .
[143] J. Leppänen,et al. Synthesis and in‐vitro/in‐vivo evaluation of orally administered entacapone prodrugs , 2001, The Journal of pharmacy and pharmacology.
[144] T. Ludden,et al. Bioavailability and newer methods of delivery of phosphorothioate radioprotectors. , 1988, Pharmacology & therapeutics.
[145] G. Amidon,et al. Oral absorption of 21-corticosteroid esters: a function of aqueous stability and intestinal enzyme activity and distribution. , 1986, Journal of pharmaceutical sciences.
[146] P. Fischer. Diketopiperazines in peptide and combinatorial chemistry , 2003, Journal of peptide science : an official publication of the European Peptide Society.
[147] R. Schowen,et al. A Mechanistic and Kinetic Study of the E-Ring Hydrolysis and Lactonization of a Novel Phosphoryloxymethyl Prodrug of Camptothecin , 2003, Pharmaceutical Research.
[148] V. Stella. Prodrugs as therapeutics , 2004 .
[149] G. Amidon,et al. Utilization of peptide carrier system to improve intestinal absorption: targeting prolidase as a prodrug-converting enzyme. , 1992, Journal of pharmaceutical sciences.
[150] F. Veronese,et al. Synthesis, characterization, and preliminary in vivo tests of new poly(ethylene glycol) conjugates of the antitumor agent 10-amino-7-ethylcamptothecin. , 2004, Journal of medicinal chemistry.
[151] W. Plunkett,et al. Metabolism and action of fludarabine phosphate. , 1990, Seminars in oncology.
[152] G. Amidon,et al. Design of prodrugs for improved gastrointestinal absorption by intestinal enzyme targeting. , 1985, Methods in enzymology.
[153] Lawrence X. Yu,et al. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome. , 2004, Current opinion in drug discovery & development.
[154] Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection. , 2004, Drugs.
[155] E. Estey,et al. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. , 1993, Seminars in oncology.
[156] S. Neau. Prodrugs for Improved Aqueous Solubility , 2008 .
[157] T. Shiba,et al. An Inversion of Configuration of Threonine and Allothreonine in the N,O-Acyl Migration Reaction with Concentrated Sulfuric Acid , 1974 .
[158] V. Stella,et al. A novel prodrug approach for tertiary amines. 2. Physicochemical and in vitro enzymatic evaluation of selected N-phosphonooxymethyl prodrugs. , 1999, Journal of pharmaceutical sciences.
[159] T. Wadsten,et al. Polymorphism of estramustine. , 1989, Journal of pharmaceutical sciences.
[160] G. Amidon,et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. , 2004, Molecular pharmaceutics.
[161] Tomoko Ito,et al. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage. , 2003, Journal of medicinal chemistry.
[162] O. H. Chan,et al. Phosphate prodrugs of PD154075. , 2000, Bioorganic & medicinal chemistry letters.
[163] V. Stella,et al. Prodrugs , 1985, Drugs.
[164] J. Kopeček,et al. Targetable polymeric prodrugs , 1987 .
[165] C. Conover,et al. Antitumor activity of paclitaxel-2'-glycinate conjugated to poly(ethylene glycol): a water-soluble prodrug. , 1998, Anti-cancer drug design.
[166] R. Oliyai,et al. Prodrugs of Phosphonates, Phosphinates, and Phosphates , 2007 .
[167] V. Stella,et al. Novel prodrug approach for tertiary amines: synthesis and preliminary evaluation of N-phosphonooxymethyl prodrugs. , 1999, Journal of medicinal chemistry.
[168] J. Crison,et al. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.
[169] M. Zamai,et al. Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[170] T. Fujiwara,et al. Development of Anti‐influenza Drugs: II. Improvement of Oral and Intranasal Absorption and the Anti‐influenza Activity of Stachyflin Derivatives , 2000, The Journal of pharmacy and pharmacology.
[171] M. Smiley,et al. Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster. , 1996, Advances in experimental medicine and biology.
[172] R B Greenwald,et al. Drug delivery systems: water soluble taxol 2'-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. , 1996, Journal of medicinal chemistry.
[173] Y. Sugimoto,et al. TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors. , 1990, European journal of cancer.
[174] E. De Clercq,et al. In vitro, ex vivo, and in situ intestinal absorption characteristics of the antiviral ester prodrug adefovir dipivoxil. , 2000, Journal of pharmaceutical sciences.
[175] H. Groen,et al. Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide. , 1997, British Journal of Cancer.
[176] Morton B. Brown,et al. Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine , 1997, Clinical pharmacology and therapeutics.
[177] Bernard,et al. Advances in Drug Research , 1964 .
[178] C. Perry,et al. Estramustine Phosphate Sodium , 1995, Drugs & aging.
[179] S. Becker,et al. Fosamprenavir: advancing HIV protease inhibitor treatment options , 2004, Expert Opinion on Pharmacotherapy.